Singapore markets open in 3 hours 38 minutes
Straits Times Index
3,260.03 -11.54 (-0.35%) S&P 500
4,326.51 -23.42 (-0.54%) Dow
34,160.78 -7.31 (-0.02%) Nasdaq
13,352.78 -189.34 (-1.40%) BTC-USD
35,709.90 -1,321.95 (-3.57%) CMC Crypto 200
808.29 -11.22 (-1.37%)
Cassava Sciences, Inc. (SAVA)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 39.45 |
| Open | 40.54 |
| Bid | 37.56 x 900 |
| Ask | 37.80 x 1400 |
| Day's range | 37.43 - 40.56 |
| 52-week range | 17.15 - 146.16 |
| Volume | |
| Avg. volume | 4,694,195 |
| Market cap | 1.507B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | N/A |
- Zacks
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $39.45, marking a -1.42% move from the previous day.
- Zacks
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.
- Motley Fool
Where Will Cassava Sciences Be in 1 Year?
First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.
© 2022 Yahoo. All rights reserved.
